Turning Digital Health Innovation into Real-World Impact
May 14th, 2026
Seventy percent of clinical decisions rely on diagnostics, yet only about one percent of healthcare spending is allocated to them. This paradox defines modern medicine: diagnostics guide care, shape treatment pathways, and determine whether disease is caught early, but budgets remain focused on intervention rather than prevention. Lisandro Zarate, Commercial Director at Roche Diagnostics, highlights this tension: healthcare systems talk about prevention, precision medicine, and sustainability, yet funding structures remain largely reactive. Most diagnostic services, especially in publicly funded systems like Spain’s, operate under cost-per-test models, even as expectations expand to include digital integration, algorithmic analysis, and workflow optimisation.
AI promises faster, more accurate diagnoses, but its impact depends on infrastructure, regulation, and economic alignment. Data, often called healthcare’s new currency, is fragmented. Even within a single country, information is scattered across dispersed “data lakes.” Without interoperability standards, governance frameworks, storage strategies, and quality controls, algorithms cannot generate meaningful insights.
Pathology illustrates this challenge clearly. Digitising slides for AI produces multi-gigabyte files that must be securely stored for decades. Cloud strategy, archiving, cybersecurity, and regulatory compliance are not abstract concerns; they are immediate operational realities. AI’s potential is real, but foundational infrastructure must keep pace.
At the same time, patients are increasingly informed before consultations. AI symptom-checkers and probabilistic tools allow individuals to research conditions before arriving at appointments. This consumer driver speed contrasts with the deliberately regulated pace of healthcare systems, which are designed to safeguard safety and accountability. Patients are already using these tools, and healthcare systems must now adapt accordingly.
For innovators, the lesson is pragmatic. Healthcare is complex. Success requires more than a strong algorithm. It demands a deep understanding of unmet clinical needs, evidence generation, regulatory strategy, and reimbursement dynamics. Europe is not a single market: adoption in Germany does not guarantee viability in Spain or the UK.
Organisations integrating diagnostics and therapeutics, like Roche, are well-positioned. Linking early detection to targeted treatments aligns incentives across the disease continuum. As healthcare shifts toward value-based models, such integration becomes increasingly important.
The barriers to transformation are mostly structural: funding silos, regulatory frameworks, infrastructure gaps, and cultural resistance. Scientific progress is accelerating, but the systems surrounding it lag behind. Healthcare cannot “move fast and break things,” nor can it remain static. The opportunity lies in augmenting clinicians, modernising regulation, and realigning incentives toward earlier, smarter intervention. AI and advanced diagnostics are ready, but the systems must now catch up.
